These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35680627)

  • 1. [Influencing factors of iron metabolism assessment in patients with myelodysplastic syndrome: A retrospective study].
    Zhang Y; Xiao C; Li J; Song LX; Zhao YS; Zhao JG; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):293-299. PubMed ID: 35680627
    [No Abstract]   [Full Text] [Related]  

  • 2. [Study of iron overload assessment by T2* magnetic resonance imaging in patients with myelodysplastic syndromes].
    Song LL; Lu HY; Xiao C; Wu LY; Wu D; Su JY; Zhou LY; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):222-226. PubMed ID: 30929390
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative Study on Iron Content Detection by Energy Spectral CT and MRI in MDS Patients.
    Zhang Y; Xiao C; Li J; Song LX; Zhao YS; Han S; Li ZW; Guo C; Zhao JG; Chang CK
    Front Oncol; 2021; 11():646946. PubMed ID: 33828991
    [No Abstract]   [Full Text] [Related]  

  • 4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients].
    Zhang Y; Xiao C; Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1027-32. PubMed ID: 25130822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world.
    Xiao C; Zhang Y; Zhao JG; Song LX; Zhao YS; Jia Y; Guo J; Han S; Li ZW; Guo C; Li X; Chang CK
    Hematology; 2021 Dec; 26(1):123-133. PubMed ID: 33491605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of abnormal iron metabolism parameters and iron overload in patients with myelodysplastic syndromes].
    Song LL; Zheng QQ; Xiao C; Guo J; Wu D; Su JY; Zhou LY; Chang CK
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):903-907. PubMed ID: 27801326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of Hepcidin in transfusion dependent myelodysplastic syndrome patients and its clinical significance].
    Qin Y; Liu H; Ruan S; Cai YF; You XF; Song GQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):758-61. PubMed ID: 22339912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes.
    Gu S; Song X; Zhao Y; Guo J; Fei C; Xu F; Wu L; Zhang X; Zhao J; Chang C; Li X
    Hematology; 2013 Sep; 18(5):286-94. PubMed ID: 23540794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
    Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
    de Montalembert M; Ribeil JA; Brousse V; Guerci-Bresler A; Stamatoullas A; Vannier JP; Dumesnil C; Lahary A; Touati M; Bouabdallah K; Cavazzana M; Chauzit E; Baptiste A; Lefebvre T; Puy H; Elie C; Karim Z; Ernst O; Rose C
    PLoS One; 2017; 12(3):e0172147. PubMed ID: 28257476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labile plasma iron, more practical and more sensitive to iron overload in myelodysplastic syndromes.
    Gu S; Xv Y; Fei C; Xiao C; Guo J; Zhao Y; Xv F; Li X; Chang C
    Hematology; 2017 Jan; 22(1):9-15. PubMed ID: 27684730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study.
    Cancado R; Watman NP; Lobo C; Chona Z; Manzur F; Traina F; Park M; Drelichman G; Zarate JP; Marfil L
    Hematology; 2018 Oct; 23(9):676-682. PubMed ID: 29663858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Iron Overload in Patients with Acute Leukemia and Myelodysplastic Syndrome on Hepatic and Endocrine functions.
    Yassin MA; Soliman A; De Sanctis V; Hmissi SM; Abdulla MAJ; Ekeibed Y; Ismail O; Nashwan A; Soliman D; Almusharaf M; Hussein R
    Acta Biomed; 2018 Apr; 89(3-S):18-22. PubMed ID: 29633728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac iron overload in transfusion-dependent patients with myelodysplastic syndromes.
    Roy NB; Myerson S; Schuh AH; Bignell P; Patel R; Wainscoat JS; McGowan S; Marchi E; Atoyebi W; Littlewood T; Chacko J; Vyas P; Killick SB
    Br J Haematol; 2011 Aug; 154(4):521-4. PubMed ID: 21689086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MRI monitoring in diagnosis and follow-up of iron overload].
    Zhang Q; Hou B; Wang L; Du Y; Han B; Feng F
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):302-6. PubMed ID: 25916291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.
    Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G; Schetelig J; Ehninger G; Theurl I; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2012 Dec; 18(23):6460-8. PubMed ID: 22991415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.